Search clinical trials for: neoadjuvant trastuzumab

Total 4339 results

Henan Cancer Hospital

Not yet recruiting

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
The Netherlands Cancer Institute
Seagen Inc.

Recruiting

Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study (TRAIN-4)

Breast Cancer

Netherlands
Xuekui Liu

Not yet recruiting

A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. (B2023-153)

Oral Squamous Cell Carcinoma
Biocon Biologics UK Ltd

Not yet recruiting

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Youzhi Zhu

Recruiting

Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

Breast Cancer Female

China
Wuhan Union Hospital, China

Recruiting

A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer

Breast Cancer | Neoadjuvant

China
Cancer Institute and Hospital, Chinese Academy...
Chinese Academy of Medical Sciences Cancer Hospital，Shanxi Center; Chinese... and other collaborators

Not yet recruiting

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Breast Cancer | Neoadjuvant Therapy

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

HER2-positive Breast Cancer

China
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Breast Cancer | HER2-positive Breast Cancer

China
Institut Català d'Oncologia
Fundación Sociedad Española de Oncologia Médica; Instituto de Salud Carlos III and other collaborators

Recruiting

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer (BiOnHER)

Neoplasms | Breast Cancer | HER2-positive Breast Cancer

Spain
Karolinska University Hospital

Recruiting

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (ARIADNE)

Breast Cancer

Sweden
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab

HER2-positive Breast Cancer | Early-stage Breast Cancer | Adjuvant Treatment After Trastuzumab | RCB Classification 1-2 | Neratini

China
Consorzio Oncotech
Roche Pharma AG

Recruiting

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Breast Cancer

Italy
Cancer Trials Ireland

Recruiting

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

HER2-positive Breast Cancer

Ireland
West German Study Group
AstraZeneca

Not yet recruiting

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV)

HER2-positive Early Breast Cancer

Germany
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Breast Cancer

China
Shengjing Hospital

Recruiting

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Breast Cancer

China
Fudan University

Recruiting

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)

Breast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)

China
Daping Hospital and the Research Institute of Surgery...

Recruiting

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Gastric Cancer | Rectal Cancer | Chemotherapy Effect | Radiotherapy | Immunotherapy

China
Shengjing Hospital

Recruiting

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Stage II-III Breast Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study for the Neoadjuvant Treatment of Breast Cancer

Breast Cancer

China
German Cancer Research Center

Recruiting

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Early-stage Breast Cancer

Germany
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche

Recruiting

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program)

Breast Cancer

France
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Breast Cancer

China
Xijing Hospital

Not yet recruiting

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer
National Institute of Oncology, Hungary

Not yet recruiting

Neoadjuvant Treatment of Breast Cancer

Breast Cancer

Hungary
Fudan University

Recruiting

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer (NeoTPPF)

HER2-positive Breast Cancer | Estrogen Receptor-positive Breast Cancer

China
Institut fuer Frauengesundheit
Samsung Bioepis Co., Ltd.

Recruiting

Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) (NeoON)

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Female

Germany
National Cancer Center Hospital East
Daiichi Sankyo Co., Ltd.

Recruiting

Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
AC Camargo Cancer Center

Recruiting

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer (HER2Cell)

Breast Neoplasms | HER2-positive Breast Cancer | Circulating Tumor Cell

Brazil
Shengjing Hospital

Not yet recruiting

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Breast Cancer

China
Ottawa Hospital Research Institute

Recruiting

Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy

Breast Cancer

Canada
West China Hospital

Recruiting

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

Breast Cancer

China
Tianjin Medical University Cancer Institute and...
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer (Pyramid)

HER2+ Early or Locally Advanced Breast Cancer
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

Neoadjuvant Therapies for HER2+ Breast Cancer

China
Guangdong Provincial People's Hospital

Not yet recruiting

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
Ahmet Bilici
Bezmialem Vakif University; Koç University; Ege University; Akdeniz University; Inonu... and other collaborators

Recruiting

The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy (HER2PATH)

Breast Cancer

Turkey
Peking University People's Hospital

Recruiting

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients

HER2-positive Early Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Breast Cancer

China
Fundacio Clinic Barcelona
Roche Pharma AG; SOLTI Breast Cancer Research Group

Recruiting

Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy (ELPIS)

Stage I Breast Cancer | HER2-positive Breast Cancer

Spain
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer

Breast Cancer,Her2 Positive

China
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Not yet recruiting

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) (ELPIS)

Mammary Cancer

Spain
Hebei Medical University Fourth Hospital

Not yet recruiting

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Breast Cancer
Sun Yat-sen University

Not yet recruiting

Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab (PRETTY)

Breast Cancer

China
Ruijin Hospital

Recruiting

Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer (NeoPATH)

Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer

China
University of Chicago

Recruiting

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III

Nigeria
Hebei Medical University Fourth Hospital
OrigiMed

Recruiting

Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer

Prospective | Observational

China
NSABP Foundation Inc
Genentech, Inc.; Celcuity, LLC

Recruiting

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12)

HER2-negative Breast Cancer

United States
Qamar Khan

Recruiting

Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer (HERMET)

HER2-positive Breast Cancer

United States
Shi Yanxia

Recruiting

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer (PERS)

Breast Cancer | Effects of Chemotherapy | Breast Cancer Model

China

3

Subscribe